Medical cannabis for the treatment of inflammation

Natural Product Communications

Volumn 13, Issue 3, 2018, Pages 249-254

  Namdar, Dvory ^a   Koltai, Hinanit ^a  

^a VOLCANI CENTER   (Israel)

Author keywords

Cannabinoids; Cannabis sativa; Inflammatory bowel diseases; Inflammatory neuronal diseases; Inflammatory skin diseases.; Therapeutic effect

Indexed keywords

CANNABIDIOL; CANNABIGEROL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; MEDICAL CANNABIS; NABILONE; PLACEBO; TETRAHYDROCANNABINOLIC ACID;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CROHN DISEASE; CYTOKINE RELEASE; DNA METHYLATION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MELANOMA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PSORIASIS; REMISSION; SYSTEMIC SCLEROSIS; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS;

EID: 85048179830     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x1801300304     Document Type: Article

References (93)

1. Mechoulam R, Gaoni Y. (1965) Hashish—iv: The isolation and structure of cannabinolic, cannabidiolic and cannabigerolic acids. Tetrahedron, 21, 1223–1229.
2. Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A. (2016) Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. Journal of Natural Products, 79, 324–331.
3. Grotenhermen F, Russo E. (2002) Cannabis and Cannabinoids-Pharmacology, Toxicology, and Therapeutic Potential. Grotenhermen F, (Eds.). Binghamton, New York. 55?65.
4. 9-THC) on humans. Toxicology, 44, 461–467.
5. Zias JE, Stark H, Seligman J, Levy R, Werker E, Breuer A, Mechoulam R. (1993) Early medical use of cannabis. Nature, 363, 215.
6. Merrillees RS. (1962) Opium trade in the Bronze Age Levant. Antiquity, XXXVI, 287–292.
7. Merlin MD. (2003) Archaeological evidence for the tradition of psychoactive plant use in the Old World. Economical Botany, 57, 295–323.
8. Namdar D, Amrani A, Kletter R. (2015) Chapter 17: Scopolin in Iron Age juglets from the Philistine repository pit of Yavneh, In Yavneh II. Kletter, R., Ziffer, I., Zwickel, W. (Eds). Orbis Biblicus et Orientalis, Academic Press, Fribourg. 214–223.
9. Gadot Y, Finkelstein I, Iserlis M, Maeir AM, Nahshoni P, Namdar D. (2014) Tracking down cult. Production, function and content of chalices in Iron Age Philistia. Tel Aviv, 41, 54–75.
10. Pennacchio M, Jefferson LV, Havens K. (2010) Uses and Abuses of Plant-Derived Smoke. Its Ethnobotany as Hallucinogen, Perfume, Incense, and Medicine. Oxford University Press, Oxford, 102.
11. Lynch ME, Campbell F. (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72, 735?744.
12. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. (2013) Low dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain, 14, 136?148.
13. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. (2008) A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain, 9, 506?521.
14. Porter BE, Jacobson C. (2013) Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behavior, 29, 574?577.
15. Slatkin NE. (2007) Cannabinoids in the Treatment of Chemotherapy-Induced Nausea and Vomiting: Beyond Prevention of Acute Emesis. The Journal of Supportive Oncology, 5, Sup. 3, 1–9.
16. Kogan NM, Mechoulam R. (2007) Cannabinoids in Health and Disease. Dialogues in Clinical Neuroscience, 9, 413–430.
17. Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. (2012) Smoked cannabis for spasticity in multiple sclerosis. A randomized, placebo-controlled trial. Canadian Medical Association Journal, 10, 1143?1150.
18. Mestre L, Correa F, Docagne F, Ortega-Guitiérrez S, Arévalo-Martín A, Molina-Holgado E, Borrell J, Guaza C. (2006) Cannabinoid system and neuroinflammation: Therapeutic perspectives in multiple sclerosis. Revue Neurologique, 43, 541–548.
19. Rog DJ, Nurmikko TJ, Friede T, Young CA. (2005) Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65, 812?819.
20. Wade DT, Makela P, Robson P, House H, Bateman C. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis, 10, 434?441.
21. Tomida I, Pertwee RG, Azuara-Blanco A. (2004) Cannabinoids and glaucoma. British Journal of Ophthalmology, 88, 708–713.
22. Tashkin DP, Shapiro BJ, Frank IM. (1974) Acute effects of smoked marijuana and oral delta 9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. The American Review of Respiratory Disease, 109, 420–428.
23. ElSohly MA, Slade D. (2005) Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Science, 78, 539–548.
24. Mechoulam R, Parker LA, Gallily R. (2002) Cannabidiol: An overview of some pharmacological aspects. Journal of Clinical Pharmacology, 42, 11S–19S.
25. Mechoulam R, Shani A, Edery H, Grunfeld Y. (1970) Chemical basis of hashish activity. Science, 169, 611–612.
26. Radwan MM, ElSohly MA, Slade D, Ahmed SA, Wilson L, El-Alfy AT, Khan IA, Ross SA. (2008) Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry, 69, 2627–2633.
27. Appendino G, Giana A, Gibbons S, Maffei M, Gnavi G, Grassi G, Sterner O. (2008) A polar cannabinoid from Cannabis sativa var. Carma. Natural Product Communications, 3, 1977–1980.
28. Flores-Sanchez IJ, Verpoorte R. (2008) Secondary metabolism in cannabis. Phytochemical Review, 7, 615–639.
29. Ahmed SA, Ross SA, Slade D, Radwan MM, Khan IA, ElSohly MA. (2008) Structure determination and absolute configuration of cannabichromanone derivatives from high potency Cannabis sativa. Tetrahedron Letters, 49, 6050–6053.
30. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bronner TI. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561–564.
31. Munro S, Thomas KL, Abu-Shaar M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
32. Grotenhermen F, Russo E. (2004) Pharmacology of cannabinoids. Neuroendocrinology Letters, 25, 14–23.
33. Breivogel CS, Griffin G, Di Marzo V, Martin BR. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology, 60, 155–63.
34. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R. (2003) Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice. Evidence for a “CB3” receptor. European Journal of Pharmacology, 461, 27–34.
35. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson‘s disease. The Official Journal of the Federation of American Societies for Experimental Biology, 14, 1432–1438.
36. Wiley JL, Martin BR. (2002) Cannabinoid pharmacology. Implications for additional cannabinoid receptor subtypes. Chemistry and Physics of Lipids, 121, 57–63.
37. Russo EB. (2011) Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163, 1344–1364.
38. Sartor RB. (2006) Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. Nature Reviews Gastroenterology Hepatology, 3, 390–407.
39. Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. (2011) Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biological and Pharmaceutical Bulletin, 34, 774–778.
40. Sturm A, Dignass AU. (2008) Epithelial restitution and wound healing in inflammatory bowel disease. World Journal of Gastroenterology, 14, 348.
41. D'Haens GR, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P. (2014) Future directions in inflammatory bowel disease management. Journal of Crohns Colitis, 8, 726–734.
42. Izzo AA, Camilleri M. (2009) Cannabinoids in intestinal inflammation and cancer. Pharmacological Research, 60, 117–125.
43. Schicho R, Storr M. (2013) Cannabis finds its way into treatment of Crohn's disease. Pharmacology, 93, 1–3.
44. Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. (2011) Treatment of Crohn’s disease with cannabis: An observational study. Israel Medical Association Journal, 13, 455–458.
45. Naftali T, Schleider LB, Dotan I, Lansky EP, Benjaminov FS, Konikoff FM. (2013) Cannabis induces a clinical response in patients with Crohn's disease. A prospective placebo-controlled study. Clinical Gastroenterology Hepatology, 11:1276–1280.
46. Wright K, Duncan M, Sharkey K. (2008) Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. British Journal of Pharmacology, 153, 263–270.
47. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. (2009) Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflammatory Bowel Disease, 15, 1678–1685.
48. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley P. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology, 152, 1092–1101.
49. Stan?i? A, Jandl K, Hasenöhrl C, Reichmann F, Marsche G, Schuligoi R, Heinemann A, Storr M, Schicho R. (2015) The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterology and Motility, 27, 1432–1445.
50. Greineisen WE, Turner H. (2010) Immunoactive effects of cannabinoids: Considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. International Immunopharmacology, 10, 547–555.
51. Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L. (2013) Cannabidiol in inflammatory bowel diseases: A brief overview. Phytotherapy Research, 27, 633–636.
52. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology, 6, 245–50.
53. Costa B, Parolaro D, Colleoni M. (1996) Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. European Journal of Pharmacology, 313, 17–24.
54. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. (2001) Molecular targets for cannabidiol and its synthetic analogues. Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 134, 845–52.
55. Mechoulam R, Hanuš L. (2002) Cannabidiol. An overview of some chemical and pharmacological aspects. Part I. Chemical aspects. Chemistry and physics of lipids, 121, 35–43.
56. Bornheim LM, Grillo MP. (1998) Characterization of cytochrome P450 3A inactivation by cannabidiol. Possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chemistry Research of Toxicology, 11, 1209–1216.
57. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. (1998) The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 76, 189–99.
58. Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. (1981) Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia, 37, 1090–1092.
59. Hunt CA, Jones RT, Herning RI, Bachman J. (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. Journal of Pharmacokinetic and Biopharmacology, 9, 245–60.
60. Pagano E, Capasso R, Piscitelli F, Romano B, Parisi OA, Finizio S, Lauritano A, Di Marzo V, Izzo AA, Borrelli F. (2016) An orally active cannabis extract with high content in cannabidiol attenuates chemically-induced intestinal inflammation and hypermotility in the mouse. Frontiers in Pharmacology, 7, 341.
61. Hill TDM, Cascio MG, Romano B, Duncan M, Pertwee RG, Williams CM, Whalley BJ, Hill, AJ. (2013) Cannabidivarin?rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor?independent mechanism. British Journal of pharmacology, 170, 679–692.
62. Castaneda FE, Walia B, Vijay–Kumar M, Patel NR, Roser S, Kolachala VL, Rojas M, Wang L, Oprea G, Garg P, Gewirtz AT. (2005) Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice. Central role of epithelial-derived MMP. Gastroenterology, 129, 1991–2008.
63. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA. (2013) Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85, 1306-1316.
64. Ihenetu K, Molleman A, Parsons ME, Whelan CJ. (2003) Inhibition of Interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. European Journal of Pharmacology, 458, 207–215.
65. 9-Tetrahydrocannabinolic Acid that interacts with additional compounds in cannabis extracts. Cannabis and Cannabinoid Research, 2, 167–182.
66. Maccarrone M, Battista N, Centonze D. (2007) The endocannabinoid pathway in Huntington's disease. A comparison with other neurodegenerative diseases. Progress in Neurobiology, 81, 349–379.
67. Brotchie JM. (2003) CB1 cannabinoid receptor signalling in Parkinson's disease. Current Opinion in Pharmacology, 3, 54–61.
68. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, Bernardi G, Brusa L, Pierantozzi M, Stanzione P, Maccarrone M. (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Annals of Neurology, 57, 777–779.
69. Kreitzer AC, Malenka RC. (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature, 445, 643–647.
70. Sieradzan KA, Fox SH, Hill M, Dick JPR, Crossman AR, Brotchie JM. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease. A pilot study. Neurology, 57, 2108–2111.
71. Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP. (2004) Cannabis for dyskinesia in Parkinson’s disease. A randomized double-blind crossover study. Neurology, 63, 1245–1250.
72. del Valle AA. (2006) Implication of cannabinoids in neurological diseases. Cellular and Molecular Neurobiology, 26, 577–589.
73. Lastres-Becker I, Fernandez-Ruiz J. (2006) An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Current Medical Chemistry, 13, 3705–3718.
74. Garcia-Arencibia M, Garcia C, Fernandez-Ruiz J. (2009) Cannabinoids and Parkinson Disease. CNS Neurological Disorder Drug Targets, 8, 432–439.
75. Ritchie K, Kildea D. (1990) Is senile dementia “age-related” or “ageing-related”? - evidence from meta-analysis of dementia prevalence in the oldest old. Lancet, 346, 931–934.
76. Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. (1989) Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA-1 family. Neuroscience Letters, 101, 288–292.
77. Bachurin SO. (2003) Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease. Medical Research Review, 23, 48–88.
78. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J. (1996) Acetylcholinesterase accelerates assembly of amyloid-?-peptides into Alzheimer's fibrils. Possible role of the peripheral site of the enzyme. Neuron, 16, 881–891.
79. Alvarez A, Alarcón R, Opazo C, Campos EO, Muñoz FJ, Calderón FH, Dajas F, Gentry MK, Doctor BP, De Mello FG, Inestrosa NC. (1998) Stable complexes involving acetylcholinesterase and amyloid-? peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. Journal of Neuroscience, 18, 3213–3223.
80. Bartolini M, Bertucci C, Cavrini V, Andrisano V. (2003) ?-Amyloid aggregation induced by human acetylcholinesterase. Inhibition studies. Biochemical Pharmacology, 65, 407–416.
81. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS. (2005) Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology, 65, 404–411.
82. Carmo Carreiras M, Mendes E, Jesus Perry M, Paula Francisco A, Marco-Contelles J. (2013) The multifactorial nature of Alzheimer’s disease for developing potential therapeutics. Current Topics in Medicinal Chemistry, 13, 1745–1770.
83. Eubanks LM, Rogers CJ, Beuscher IV AE, Koob GF, Olson AJ, Dickerson TJ, Janda KD. (2006) A molecular link between the active component of marijuana and Alzheimer's disease pathology. Molecular Pharmaceutics, 3, 773–777.
84. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL, Guzmán M. (2003) Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. The Journal of Clinical Investigation, 111, 43–50.
85. Bíró T, Tóth BI, Haskó G, Paus R, Pacher P. (2009) The endocannabinoid system of the skin in health and disease. Novel perspectives and therapeutic opportunities. Trend in Pharmacological Sciences, 30, 411–420.
86. Wilkinson JD, Williamson EM. (2007) Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Sciences, 45, 87–92.
87. Paradisi A, Pasquariello N, Barcaroli D, Maccarrone M. (2008) Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. Journal of Biological Chemistry, 283, 6005–6012.
88. Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G,Malumbres M,Guzmán M. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. The FASEB journal, 20, 2633–2635.
89. Dobrosi N, Tóth BI, Nagy G, Dózsa A, Géczy T, Nagy L, Zouboulis CC, PausR, Kovács L,Bíró T. (2008) Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. The FASEB Journal, 22, 3685–3695.
90. Pulvirenti N, Nasca MR. Micali G. (2007) Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects. A pilot study. Acta Dermatovenerologica Croatica, 15, 80–83.
91. Lambert DM. (2007) Allergic contact dermatitis and the endocannabinoid system. From mechanisms to skin care. ChemMedChem, 2, 1701–1702.
92. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O,Distler JH. (2009) The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis & Rheumatology, 60, 1129–1136.
93. Pucci M, Rapino C, Di Francesco A, Dainese E, D'Addario C, Maccarr M. (2013) Epigenetic control of skin differentiation genes by phytocannabinoids. British Journal of Pharmacology, 170, 581–591.